Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Diabetic Retinopathy (DR) Clear all

Conditions: Age-Related Macular Degeneration
Interventions: occupational therapy interventions for low vision care; Combination Product
Lead sponsor: MCPHS University; Other
Eligibility: 50 Years to 100 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Diabetic Retinopathy (DR)
Interventions: Diabetic Retinopathy screening Point of Care Artificial Intelligence; Diagnostic Test
Lead sponsor: Centro De Salud La Comunidad De San Ysidro Inc DBA: San Ysidro Health; Other
Eligibility: 22 Years and older
Enrollment: 548 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Chula Vista, California • San Diego, California

Conditions: Diabetic Retinopathy
Interventions: Tarcocimab, Sham injection; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 38
States / cities: Tucson, Arizona • Fullerton, California • Glendale, California + 34 more

Conditions: Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)
Interventions: ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, Topical Steroid, ABBV-RGX-314 Dose 4, Aflibercept; Genetic · Drug · Biological
Lead sponsor: AbbVie; Industry
Eligibility: 25 Years to 89 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 25
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 21 more

Conditions: Diabetic Retinopathy (DR)
Interventions: SaMD intended for the detection of diabetic retinopathy in adults with diabetes., An AI/ML-based Software as a Medical Device (SaMD) for the automated detection of diabetic retinopathy in adults with diabetes.; Device
Lead sponsor: Digital Diagnostics, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Retinal Vasculitis
Interventions: aflibercept 2 mg; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 550,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Diabetic Retinopathy (DR)
Interventions: automatic analysis of fundus images performed by the software tool based on artificial intelligence; Device
Lead sponsor: Centervue SpA; Industry
Eligibility: 22 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Glaucoma, AMD, Diabetic Retinopathy (DR)
Interventions: Chronic Disease Intervention CDI; Other
Lead sponsor: Interstat LLC; Other
Eligibility: 18 Years to 99 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: White Plains, New York

Conditions: Diabetic Macular Edema, Diabetic Retinopathy
Interventions: ADVM-022; Genetic
Lead sponsor: Adverum Biotechnologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 6
States / cities: Beverly Hills, California • Reno, Nevada • Philadelphia, Pennsylvania + 3 more

Conditions: Diabetic Retinopathy (DR)
Interventions: PRONTO-EYE; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Mid-peripheral Drusen Formation, Diabetic Macular Edema (DME)
Interventions: Photobiomodulation, Ketogenic diet; Behavioral
Lead sponsor: Bristlecone Health, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Eagan, Minnesota

Conditions: Diabetic Retinopathy
Interventions: Photography of the retina, Retinal photography; Procedure
Lead sponsor: Digital Diagnostics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: Mesa, Arizona • Phoenix, Arizona • Cedar Rapids, Iowa + 2 more

Conditions: Macular Degeneration, Diabetic Retinopathy, Hippel-Landau Disease, Mitochondria
Interventions: Feasibility Study - Imaging System; Procedure
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Retinopathy (DR), Macular Edema (ME)
Interventions: Animated Videos; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetic Retinopathy
Interventions: Finerenone (BAY94-8862); Drug
Lead sponsor: Bayer; Industry
Eligibility: Not listed
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: Chula Vista, California • El Centro, California • Fort Lauderdale, Florida + 7 more

Conditions: Diabetic Retinopathy (DR)
Interventions: Fundus Image Grading; Diagnostic Test
Lead sponsor: Artelus AI; Industry
Eligibility: 21 Years and older
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Oxford, North Carolina • Raleigh, North Carolina

Conditions: Diabetic Retinopathy
Interventions: OTT166, Vehicle control; Drug
Lead sponsor: OcuTerra Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 67
States / cities: Peoria, Arizona • Phoenix, Arizona • Beverly Hills, California + 59 more

Conditions: Diabetic Retinopathy, DR
Interventions: Standard of Care, Aflibercept; Drug
Lead sponsor: AbbVie; Industry
Eligibility: Not listed
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 20
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 17 more

Conditions: Stargardt Disease, Diabetic Retinopathy, Macular Degeneration (Age Related)
Interventions: Anterior Chamber (AC) Tap; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetic Retinopathy, DR, Diabetic Mellitus
Interventions: AEYE-DS Software; Device
Lead sponsor: AEYE Health Inc; Industry
Eligibility: 22 Years and older
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetic Macular Edema, Diabetic Retinopathy
Interventions: 6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept; Biological
Lead sponsor: Adverum Biotechnologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 13
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 10 more

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: Point of Care Autonomous AI diabetic retinopathy exam; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 8 Years to 21 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetic Retinopathy
Interventions: Fenofibrate, Placebo; Drug · Other
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years to 80 Years
Enrollment: 563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 66
States / cities: Glendale, California • Huntington Beach, California • Loma Linda, California + 55 more

Conditions: Retinal Vasculitis
Interventions: aflibercept 2mg; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 290,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Tarrytown, New York

Search by objective public record fields.

The Role of Occupational Therapy for Improving Medication Management for Persons With AMD, DR and Glaucoma

Diabetic Retinopathy Screening Point-of-Care Artificial Intelligence

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)

Pivotal Trial for an Automated AI-based System for Detection of Diabetic Retinopathy

A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)

Preliminary Assessment of an Automated Tool for Diabetic Retinopathy Screening

A Real-World Study of Interventional Clinical Outcomes in Patients With Open Angle Glaucoma and Other Chronic Eye Diseases

Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)

Using Implementation Science to Adapt a Targeted Transportation Intervention for Patients With Diabetic Retinopathy (PRONTO-EYE)

Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention

Computer Detection of Diabetic Retinopathy Compared to Clinical Examination

Metabolic Mapping to Measure Retinal Metabolism

Video Intervention to Improve Understanding of Diabetic Retinopathy at Zuckerberg San Francisco General Hospital and Trauma Center

A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)

Assessment of AI Program 'DRISTi' as a Screening Tool

Nesvategrast (OTT166) in Diabetic Retinopathy (DR)

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy

Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy

Efficacy and Safety of AEYE Diagnostic Screening (AEYE-DS) Software Device for Detection of Diabetic Retinopathy From Digital Funduscopic Images

ADVM-022 Intravitreal Gene Therapy for DME

ACCESS: AI for pediatriC diabetiC Eye examS Study

Fenofibrate for Prevention of DR Worsening

Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study